#bioAffinity

Thiard News@F4F

@newsen.bsky.social

5 months ago

bioAffinity Technologies Secures $1.8 Million Direct Financing for Noninvasive Cancer Detection Test bioAffinity Technologies has successfully closed a $1.8 million financing round, aimed at enhancing its revolutionary lung cancer detection test, CyPath® Lung.

bioAffinity Technologies Secures $1.8 Million Direct Financing for Noninvasive Cancer Detection Test #USA #Jersey_City #WallachBeth #bioAffinity #CyPath

Thiard News@F4F

@newsen.bsky.social

7 months ago

WallachBeth Capital Completes $1.2 Million Private Placement for bioAffinity Technologies WallachBeth Capital announces the successful closure of a $1.2 million private placement with bioAffinity Technologies, enhancing financial connectivity.

WallachBeth Capital Completes $1.2 Million Private Placement for bioAffinity Technologies #United_States #Jersey_City #Private_Placement #WallachBeth #bioAffinity

CyPath® Lung

@cypathlung.bsky.social

7 months ago

“CyPath® Lung gave us the clarity we needed to act early,” said Dr. Gordon Downie, CMO, referring to a Stage 1A mucinous adenocarcinoma missed by other diagnostics.
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity

CyPath® Lung

@cypathlung.bsky.social

8 months ago

Exciting data from Dr. Dave Elzi at the #RNATherapeutics Conference: the double knockdown of specific proteins on the cell membrane selectively kills cancer cells while sparing healthy tissue. A powerful step forward in RNA-based precision oncology. #siRNA #CancerResearch #RNAinnovation #bioAffinity

CyPath® Lung

@cypathlung.bsky.social

8 months ago

New Chinese patent is another milestone in our mission to develop smarter, more selective cancer therapies.
🔬 Targeted
✅ Non-toxic to normal cells
🌍 Globally protected IP
Read the news release at bit.ly/4kUYoET
#bioAffinity #Cancer #NewPatent #siRNA #PrecisionMedicine #ChinaPatent #CancerTherapy

CyPath® Lung

@cypathlung.bsky.social

9 months ago

Maria will bring her expertise in lung health & business to advance the ALA's mission. We're committed to noninvasive diagnostics like CyPath® Lung to save lives. Congratulations Maria!
Read it: bit.ly/3Zq8LYN

#CyPathLung #bioAffinity #LungHealth #LungCancer #ALA #Healthcare

CyPath® Lung

@cypathlung.bsky.social

9 months ago

bioAffinity has been granted U.S. Patent No. 12,305,171 for our siRNA-based method that selectively kills cancer cells by targeting CD320 & LRP2 receptors.

First target: topical skin cancer treatment
More to come.
🔗 bit.ly/3ZCRGuF

#CancerResearch #Biotech #SkinCancer #Innovation #bioAffinity

Thiard News@F4F

@newsen.bsky.social

10 months ago

WallachBeth Capital Facilitates bioAffinity Technologies' $3.25 Million Offering for Noninvasive Cancer Detection WallachBeth Capital has announced the pricing of bioAffinity Technologies' $3.25 million securities offering aimed at advancing noninvasive cancer detection technology.

WallachBeth Capital Facilitates bioAffinity Technologies' $3.25 Million Offering for Noninvasive Cancer Detection #USA #cancer_detection #Jersey_City,_NJ #WallachBeth #bioAffinity

CyPath® Lung

@cypathlung.bsky.social

10 months ago

Efficiency measures for its flagship product, CyPath® Lung, are projected to decrease the time required to acquire sample data for analysis by nearly 50% and reduce the cost of sample processing by approximately 60%.

🔗 Read the full press release: bit.ly/bioAffTech

#CyPathLung #bioAffinity

Thiard News@F4F

@newsen.bsky.social

1 year ago

WallachBeth Capital Completes Warrant Inducement Deal with bioAffinity Technologies for $1.4 Million WallachBeth Capital announced the successful closure of a warrant inducement transaction with bioAffinity Technologies, securing $1.4 million in proceeds.

WallachBeth Capital Completes Warrant Inducement Deal with bioAffinity Technologies for $1.4 Million #United_States #Jersey_City #Warrant_Inducement #WallachBeth #bioAffinity